Abstract:Background: Recently, the osteogenic potential of Adiponectin-labeled adipogenic lineage progenitors (Adipoq-lineage progenitors) in bone marrow has been observed to support bone maintenance and repair. However, little is known about the function of Schnurri-3 (SHN3, also known as HIVEP3) in other mesenchymal lineage cells, apart from its negative regulation of bone formation on osteoblasts.Method: In this study, we used single-cell RNA sequencing (scRNA-seq) profiling to demonstrate that Adipoq-lineage progenitors express higher levels of Shn3 compared to other mesenchymal cell populations in mice and humans. To investigate the role of SHN3 in Adipoq-lineage progenitors, we generated a murine model specifically harboring a Shn3-deficient allele in Adipoq-expressing cells. Information of mice body weight was collected weekly to generate body weight curve. Bone phenotype was analyzed using micro-CT and histomorphometric studies. To eliminate the role of peripheral adipose tissue on bone, we collected adipose wet weight, performed intraperitoneal glucose tolerance tests and intraperitoneal insulin tolerance tests, and conducted a fat-transplantation study. Osteoblast and osteoclast functions were assessed through toluidine blue staining and TRAP staining, respectively. We further investigated the effect of Shn3 depletion on the differentiation of Adipoq-lineage progenitors through immunostaining and in vitro differentiation assays. Finally, we evaluated whether Shn3 deficiency in Adipoq-lineage progenitors affects the fracture healing process by generating bi-cortical femoral fracture models.Results: Depletion of Shn3 in Adipoq-lineage progenitors resulted in a significant increase in trabecular bone mass and bone formation in vivo, without disrupting whole-body energy metabolism and skeletal development. Consistent with these findings, both cell-lineage tracing and functional assays revealed that Shn3 ablation effectively shifted the cell fate of Adipoq-lineage progenitors towards an osteogenic phenotype in the bone marrow. Furthermore, in vivo studies demonstrated that the lack of Shn3 in Adipoq-lineage progenitors also enhanced bone fracture healing under pathological conditions.Conclusion: Overall, our findings provide a novel strategy for targeting the osteoanabolic potential of bone marrow Adipoq-lineage progenitors as a potential treatment for bone loss-related disorders.Translational potential of this article: We have identified a novel gene target that directs the cell fate of a previously identified non-osteogenic cell population under physiological conditions. This study not only expands the therapeutic value of Shn3 ablation in treating osteoporotic or traumatic bone diseases but also provides new insights into the contribution of bone marrow Adipoq-lineage progenitors to osteogenesis. Thus, this article further supports Shn3 silencing as a valuable approach to treat osteopenia and accelerate fracture healing (see graphical abstract).

Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis

Engineering a targeted and safe bone anabolic gene therapy to treat osteoporosis in alveolar bone loss

WNT-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects

AAV-mediated delivery of osteoblast/osteoclast-regulating miRNAs for osteoporosis therapy.

AAV-mediated Delivery of Osteoblast/osteoclast-Regulating Mirnas for Osteoporosis Therapy

A bone-targeting drug-delivery system based on Semaphorin 3A gene therapy ameliorates bone loss in osteoporotic ovariectomized mice.

An Angiogenic Approach to Osteoanabolic Therapy Targeting the SHN3-SLIT3 Pathway.

Schnurri-3 inhibition suppresses bone and joint damage in models of rheumatoid arthritis

Schnurri-3 controls osteogenic fate of Adipoq-lineage progenitors in bone marrow

A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis

A Delivery System Targeting Bone Formation Surfaces to Facilitate RNAi-based Anabolic Therapy

SDSSD Peptide Modified Polyvinylamine − A Novel Bone-Targeting RNA Delivery System

Construction of Multi‐Module RNA Nanoparticles Harboring miRNA, AIE, and CH6 Aptamer for Bone Targeting and Bone Anabolic Therapy

Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery

Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold.

Adenovirus-associated anti-miRNA-214 regulates bone metabolism and prevents local osteoporosis in rats

Osteoblast-Targeting-Peptide Modified Nanoparticle for Sirna/Microrna Delivery

Targeting Skeletal Endothelium to Ameliorate Bone Loss.

Therapeutic RNA interference targeting CKIP-1 with a cross-species sequence to stimulate bone formation

Rational polyelectrolyte nanoparticles endow preosteoclast-targeted siRNA transfection for anabolic therapy of osteoporosis

A Bone-Resorption Surface-Targeting Nanoparticle to Deliver Anti-Mir214 for Osteoporosis Therapy.